Pediatric guanfacine exposures reported to the National Poison Data System, 2000-2016

Area of Science:

• Toxicology
• Pediatric Emergency Medicine
• Pharmacovigilance

Background:

• Guanfacine is a medication used to treat ADHD and hypertension.
• Pediatric exposures to medications require careful monitoring due to potential for unique adverse effects.
• Understanding exposure patterns and outcomes is crucial for public health and clinical management.

Purpose of the Study:

• To analyze trends and characteristics of pediatric guanfacine exposures reported to the National Poison Data System (NPDS) between 2000 and 2016.
• To identify common clinical manifestations, treatments, and outcomes associated with these exposures.
• To evaluate the relationship between ingested dose and clinical effect severity in pediatric patients.

Main Methods:

• Retrospective analysis of NPDS data for single-substance guanfacine ingestions in pediatric patients (0-19 years).
• Data included age, exposure circumstances, clinical effects, treatments, and duration of effects.
• Statistical analysis to compare dose-response relationships across different effect severity groups.

Main Results:

• Over 10,000 pediatric guanfacine exposures were reported, with a significant increase over the study period, particularly in 6-12 year olds.
• Most frequent clinical effects were drowsiness (39%), bradycardia (15.5%), and hypotension (10.3%).
• A statistically significant difference in ingested dose (mg/kg) was observed between patients with no/minor effects and those with moderate/major effects, though major effects were rare.

Conclusions:

• Pediatric guanfacine exposures have risen, necessitating increased awareness and preventative measures.
• Bradycardia, hypotension, and CNS depression are key clinical findings requiring prompt management.
• While major adverse effects are uncommon, prolonged observation (≥24 hours) in a healthcare facility is recommended for symptomatic pediatric patients following guanfacine exposure.